Genéricos/Novedades

Two additions to the South Korean generics market

Genéricos/Novedades | Posted 28/08/2020

In South Korea, a generic drug for the treatment of breast cancer and generic versions of Pfizer’s popular smoking cessation drug, Champix, are soon to become available. These additions to the South Korean market are likely to help it reach the US$20 billion that it is expected to reach in 2020 [1]. This recent leap in its pharmaceutical market size has been spurred on by significant government investments in generics and the fact that many originator drugs lose their patents in 2020, opening the market to generics.

Indian generics makers begin to dispatch remdesivir

Genéricos/Novedades | Posted 24/07/2020

Generic drugmakers Hetero and Cipla are among the first Indian manufacturers to dispatch a generic version of the investigational COVID-19 treatment remdesivir, which was originally developed by Gilead Sciences.

Generics of apixaban and chlorzoxazone approved in EU and US

Genéricos/Novedades | Posted 03/07/2020

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a generic version of the anticoagulant medicine apixaban. Meanwhile in the US, the Food and Drug Administration (FDA) has approved a generic version of the muscle relaxant chlorzoxazone.

Aurobindo Pharma receives FDA approval for three generics

Genéricos/Novedades | Posted 12/06/2020

India-based generics maker Aurobindo Pharma (Aurobindo) has received three approvals from the US Food and Drug Administration (FDA) in recent months, including for its generic versions of guaifenesin, fluoxetine and – via partner company Eugia Pharma – methotrexate.

COVID-19 drugs: Gilead’s remdesivir and Algernon’s alternative

Genéricos/Novedades | Posted 22/05/2020

Gilead Sciences has signed licensing agreements with five generics manufacturers based in India and Pakistan to increase production of its experimental COVID-19 drug remdesivir.

FDA approves Proventil and Daraprim generics

Genéricos/Novedades | Posted 08/05/2020

The US Food and Drug Administration (FDA) has approved the first generic version of a commonly used inhaler, marketed as Proventil, and the anti-parasitic Daraprim, which has previously been the subject of a price gouging scandal.

FDA approves lung cancer and anticoagulant generics

Genéricos/Novedades | Posted 20/03/2020

The US Food and Drug Administration (FDA) has issued a final approval for a generic version of Alimta (pemetrexed) and two new generics of Eliquis (apixaban).

Chinese company makes copy of patented coronavirus treatment remdesivir

Genéricos/Novedades | Posted 28/02/2020

China’s BrightGene has successfully produced remdesivir, an experimental treatment for coronavirus, however, patents for the drug are currently held by the American company Gilead.

EMA recommends four new generics

Genéricos/Novedades | Posted 21/02/2020

At the Committee for Medicinal Products for Human Use’s (CHMP) January 2020 meeting, the Committee recommended four new generics, and one new biosimilar, for approval.

FDA approves generics for cancer and gout

Genéricos/Novedades | Posted 31/01/2020

The US Food and Drug Administration (FDA) has approved two generic versions of Novartis’ anticancer drug Afinitor (everolimus), alongside a generic of Takeda’s gout treatment Uloric (febuxostat).